吡仑帕奈作为添加治疗及单药治疗疗效评价及真实世界研究现状

Efficacy evaluation of perampanel as add-on therapy and monotherapy and current status of real-world study

癫痫是世界上最常见的慢性神经系统疾病之一。迄今为止,在所有的抗癫痫治疗方法中,药物治疗仍然是治疗癫痫患者的基石。目前,已有20多种抗癫痫药可供临床医师选择,但只有约70%的癫痫患者可以通过抗癫痫药治疗,使癫痫发作得到充分控制。吡仑帕奈(PER)作为第三代新型抗癫痫药带来了新的作用机制和更优的药代动力学,且已在多个国家上市并投入临床使用。目前PER多用于癫痫患者的添加治疗,并取得了良好的疗效。而PER在单药治疗中的应用前景同样值得我们关注。该文对PER的药物特点、临床疗效及不良反应等进行阐述,并着重对吡仑帕奈作为添加治疗和单药治疗的临床试验疗效评价及近期真实世界应用现状进行汇总,为实际临床应用提供理论依据。

Epilepsy is one of the most common chronic nervous system diseases around the world.Up to now,pharmacotherapy remains the cornerstone treatment of patients with epilepsy among all antiepileptic therapies.There are currently more than 20 antiepileptic drugs available to clinicians,but only 70%of the patients with epilepsy can be treated by antiepileptic drugs to achieve adequate control of epileptic seizure.Perampanel(PER),as the third-generation antiepileptic drug,has a new mechanism of action and excellent pharmacokinetics and has been launched and put into clinical use in many countries.At present,PER is mainly used in the add-on therapy for patients with epilepsy and has achieved good efficacy,while further studies are needed to explore the application prospect of PER in monotherapy.This article reviews the characteristics,clinical efficacy,and adverse reactions of PER and summarizes the clinical trials and real-world application of PER as add-on therapy and monotherapy,in order to provide a theoretical basis for clinical application.